Despite the current COVID pandemic, dermatology clinical trials continue to grow across product categories and demographics. In addition, while there are concerns regarding COVID variants, dermatology clinical trials continue to expand, and researchers are searching for innovative methods for recruiting participants and conducting trials. One such tool, an eBook published by Tissue Analytics, is a new tool that helps dermatology researchers find new ways to recruit participants.
Sponsors of dermatology clinical trials need to incorporate patients’ perspectives and feedback into their studies. This is especially important when considering the burden of study participation. The patient perspective provides essential information that can enhance the study’s success and the likelihood of market adoption. Similarly, patients’ perspectives are critical for meeting the expectations of payers, insurers, and regulators. This guide overviews the patient’s perspective on dermatology clinical trials.
Initially, a patient-focused protocol is necessary to establish whether a new treatment is feasible and appropriate. Moreover, patient involvement in the protocol review process can help sponsors determine whether the study’s burden or endpoints are meaningful to patients. In addition, patient feedback can help sponsors develop compelling study messaging and improve their trial’s objective. Finally, patients’ perspectives can also inform the design of patient-facing materials such as consent forms.
A Limited Number Of Qualified Patients
While the COVID pandemic has disrupted many areas of the healthcare industry, it has did not affect dermatology clinical trials based on the dermatology CRO market. Indeed, the field of dermatology continues to grow across all product categories and demographics. But dermatologists are concerned about the potential impact COVID variants could have on in-person trials. They are therefore looking for new ways to recruit participants and conduct clinical trials. One way to ensure that dermatology clinical trials remain ethical and feasible is to adopt 3Ds.
A limited number of qualified patients has long been a major limitation of dermatology research. As a result, researchers have traditionally conducted dermatology clinical trials at limited sites. This ensures that the patient pool is homogeneous. However, this has its drawbacks. For example, patients may not be available if they suffer from a concurrent illness or taking other medications. Further, it is difficult to recruit enough patients for all the trials.
The Growing Use Of Teledermatology In Dermatology Clinical Trials
Teledermatology has seen an explosion in the past two years, with a focus on underserved communities. In addition to improving access to care, teledermatology improves health services and can help treat common skin problems. Yet a few concerns remain. For example, some physicians express concern about depersonalizing patient consultations due to telemedicine. In the face of these concerns, the growing use of teledermatology in dermatology clinical trials is one such method.
Despite its benefits, teledermatology has its downsides. For example, a clinical consult via video may not be accurate, and doctors are less likely to be able to palpate patients’ skin. In addition, patients at high risk for melanoma must undergo an in-person examination, which can prove difficult when teledermatology is used. It may also be difficult to diagnose dermatoses that are hard to detect visually, and teledermatologists should be aware of this limitation and be able to address them adequately.
Need For Greater Public Education About Dermatology Clinical Trials
Clinical trials are a vital part of modern medicine. Randomized, double-blind, placebo-controlled studies have been a major factor in developing new treatments for many diseases. For example, from 2005 to 2012, the FDA approved 188 new drugs based on the results of 448 dermatology clinical trials. These studies’ success has helped develop life-saving therapies for many conditions. But, there are many reasons why more public education about dermatology clinical trials is needed.
A growing number of dermatology clinical trials involve people of color. Although the numbers are small, ethnic minority participation has increased steadily. Therefore, it is crucial to ensure that training materials that represent skin types and ethnicities accurately judge a treatment’s efficacy. Ultimately, educating the public about dermatology clinical trials will increase their chances of success. In addition, if the public is informed, they will be better able to make informed decisions about which treatments are best for their skin type.